Impax Asset Management Group plc Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Impax Asset Management Group plc reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 64.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,115 shares of the medical research company’s stock after selling 1,987 shares during the quarter. Impax Asset Management Group plc’s holdings in Charles River Laboratories International were worth $264,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC increased its holdings in shares of Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after buying an additional 74 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $37,000. Operose Advisors LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $42,000. Covestor Ltd increased its holdings in shares of Charles River Laboratories International by 100.0% in the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock worth $49,000 after buying an additional 87 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its holdings in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 112 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

NYSE CRL opened at $246.42 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The firm’s 50 day moving average price is $252.17 and its 200-day moving average price is $219.65. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The company has a market cap of $12.69 billion, a PE ratio of 26.76, a P/E/G ratio of 2.00 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the firm earned $2.98 earnings per share. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of several analyst reports. UBS Group upped their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Robert W. Baird upped their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Argus boosted their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).